References
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA-Cancer J Clin. 2015;65:87–108.
- Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
- Klemann N, Helgstrand JT, Brasso K, et al. Antibiotic prophylaxis and complications following prostate biopsies - a systematic review. Dan Med J. 2017;64.
- Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–892.
- Walker JT, Singla N, Roehrborn CG. Reducing infectious complications following transrectal ultrasound-guided prostate biopsy: a systematic review. Rev Urol. 2016;18:73–89.
- Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189:S12–S17. discussion S17-8.
- Madden T, Doble A, Aliyu SH, et al. Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. BJU Int. 2011;108:1597–1602.
- Qi C, Malczynski M, Schaeffer AJ, et al. Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy. J Urol. 2013;190:2026–2032.
- R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2012. (Computing RFfS, editor.).
- Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013;63:521–527.
- Schaeffer AJ, Montorsi F, Scattoni V, et al. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int. 2007;100:51–57.
- Loeb S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110–1114.
- Saade EA, Suwantarat N, Zabarsky TF, et al. Fluoroquinolone-resistant escherichia coli infections after transrectal biopsy of the prostate in the veterans affairs healthcare system. Pai. 2016;1:243–257.
- Collignon PJ, Conly JM, Andremont A, et al. World Health Organization Ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies to control antimicrobial resistance from food animal production. Clin Infect Dis. 2016;63:1087–1093.
- Antsupova V, Norgaard N, Bisbjerg R, et al. Antibiotic prophylaxis for transrectal prostate biopsy-a new strategy. J Antimicrob Chemoth. 2014;69:3372–3378.
- Grabe M, Forsgren A. The effectiveness of a short perioperative course with pivampicillin/pivmecillinam in transurethral prostatic resection: bacteriological results. Scand J Infect Dis. 1986;18:575–581.
- Jeppesen N, Frimodt-Moller C. Serum concentrations and penetration into prostate of mecillinam and ampicillin. Curr Med Res Opin. 1984;9:213–218.
- Neu JC. Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics. Antimicrob Agents Ch. 1976;10:535–542.
- Juricic C, Klippel K, Sietzen W. Concentration of Amoxycillin and Clavunalate in the Prostate Tissue and in Serum: A Pharmacokinetic Study. Abstracts of the Fifteenth International Congress of Chemotherapy. Istanbul, Turkey: International Society of Chemotherapy; 1987.
- Scaglione F, Ferrara F, Logo R. Pharmacokinetics and Tissue Penetration of Clavulanic Acid and Amoxicillin Given in Combination and in a Single Intake. Abstracts of the Sixth Mediterranean Congress on Chemotherapy. Italy, Taormina: Mediterranean Society of Chemotherapy; 1988.